KOPRAN
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Kopran rises on getting no observations after USFDA inspection at API unit
** Shares of Kopran KPRN.NS up 5% to 200 rupees
** The integrated pharma co says USFDA concluded inspection at API unit in Mahad, Maharashtra with no observations
** More than 480,000 shares traded, 1.5x its 30-day moving avg
** KPRN trims YTD losses to ~6%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
** Shares of Kopran KPRN.NS up 5% to 200 rupees
** The integrated pharma co says USFDA concluded inspection at API unit in Mahad, Maharashtra with no observations
** More than 480,000 shares traded, 1.5x its 30-day moving avg
** KPRN trims YTD losses to ~6%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
Kopran Ltd Says Approved Merger Of Kopran Laboratories With Kopran Limited
March 20 (Reuters) - Kopran Ltd KPRN.NS:
APPROVED MERGER OF KOPRAN LABORATORIES WITH KOPRAN LIMITED
MERGER SWAP RATIO: 100 SHARES OF KOPRAN LTD AGAINST 45 SHARE OF KOPRAN LABORATORIES
Source text: ID:nNSEbC0JMl
Further company coverage: KPRN.NS
(([email protected];;))
March 20 (Reuters) - Kopran Ltd KPRN.NS:
APPROVED MERGER OF KOPRAN LABORATORIES WITH KOPRAN LIMITED
MERGER SWAP RATIO: 100 SHARES OF KOPRAN LTD AGAINST 45 SHARE OF KOPRAN LABORATORIES
Source text: ID:nNSEbC0JMl
Further company coverage: KPRN.NS
(([email protected];;))
Kopran Says Dividend At 3 Rupees Per Share
May 16 (Reuters) - Kopran Ltd KPRN.NS:
DIVIDEND 3 RUPEES PER SHARE
MARCH-QUARTER CONSOL NET PROFIT 186.2 MILLION RUPEES VERSUS PROFIT 80.4 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.86 BILLION RUPEES VERSUS 1.49 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: KPRN.NS
(([email protected];))
May 16 (Reuters) - Kopran Ltd KPRN.NS:
DIVIDEND 3 RUPEES PER SHARE
MARCH-QUARTER CONSOL NET PROFIT 186.2 MILLION RUPEES VERSUS PROFIT 80.4 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.86 BILLION RUPEES VERSUS 1.49 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: KPRN.NS
(([email protected];))
India's Kopran hits 1-month high on bulk deal
** Shares of pharmaceutical products maker Kopran KPRN.NS rise as much as 8.2% to one-month-high of 281 rupees
** Quant Mutual Fund bought 250,000 KPRN shares at 255.41 rupees each via a bulk deal as per NSE data
** Stock last up 6.6%; over 1.3 mln shares traded, set for most active session in a month
** Stock has gained ~13% so far in March
(Reporting by Anisha Ajith in Bengaluru)
** Shares of pharmaceutical products maker Kopran KPRN.NS rise as much as 8.2% to one-month-high of 281 rupees
** Quant Mutual Fund bought 250,000 KPRN shares at 255.41 rupees each via a bulk deal as per NSE data
** Stock last up 6.6%; over 1.3 mln shares traded, set for most active session in a month
** Stock has gained ~13% so far in March
(Reporting by Anisha Ajith in Bengaluru)
India's Kopran rises on Q3 profit jump
** Shares of Kopran KPRN.NS rise ~5% to 283.45 rupees
** Pharma company reported a two-fold rise in its Dec-qtr consol net profit
** Trading volume tops 1.7 mln, 3.5x the 30-day moving average
** Stock rose 60% in 2023 after falling 53% in 2022
(Reporting by Kashish Tandon in Bengaluru)
** Shares of Kopran KPRN.NS rise ~5% to 283.45 rupees
** Pharma company reported a two-fold rise in its Dec-qtr consol net profit
** Trading volume tops 1.7 mln, 3.5x the 30-day moving average
** Stock rose 60% in 2023 after falling 53% in 2022
(Reporting by Kashish Tandon in Bengaluru)
India's Kopran Sept-Quarter Consol Net Profit Rises
Nov 7 (Reuters) - Kopran Ltd KPRN.NS:
SEPT-QUARTER CONSOL NET PROFIT 137.7 MILLION RUPEES VERSUS PROFIT 46.5 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.53 BILLION RUPEES VERSUS 1.17 BILLION RUPEES
Source text for Eikon: ID:nBSEbKX5x1
Further company coverage: KPRN.NS
(([email protected];))
Nov 7 (Reuters) - Kopran Ltd KPRN.NS:
SEPT-QUARTER CONSOL NET PROFIT 137.7 MILLION RUPEES VERSUS PROFIT 46.5 MILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.53 BILLION RUPEES VERSUS 1.17 BILLION RUPEES
Source text for Eikon: ID:nBSEbKX5x1
Further company coverage: KPRN.NS
(([email protected];))
India's Kopran Ltd June-Quarter Consol Net Profit Falls
Aug 10 (Reuters) - Kopran Ltd KPRN.NS:
JUNE-QUARTER CONSOL NET PROFIT 27.7 MILLION RUPEES VERSUS PROFIT 76 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.17 BILLION RUPEES VERSUS 1.26 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: KPRN.NS
(([email protected];))
Aug 10 (Reuters) - Kopran Ltd KPRN.NS:
JUNE-QUARTER CONSOL NET PROFIT 27.7 MILLION RUPEES VERSUS PROFIT 76 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.17 BILLION RUPEES VERSUS 1.26 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: KPRN.NS
(([email protected];))
Kopran March-Qtr Consol Profit Falls
May 25 (Reuters) - Kopran Ltd KPRN.NS:
DIVIDEND 3 RUPEES PER SHARE
MARCH-QUARTER CONSOL PROFIT 80.4 MILLION RUPEES VERSUS PROFIT 175.1 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.49 BILLION RUPEES VERSUS 1.43 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: KPRN.NS
(([email protected];))
May 25 (Reuters) - Kopran Ltd KPRN.NS:
DIVIDEND 3 RUPEES PER SHARE
MARCH-QUARTER CONSOL PROFIT 80.4 MILLION RUPEES VERSUS PROFIT 175.1 MILLION RUPEES
MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.49 BILLION RUPEES VERSUS 1.43 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: KPRN.NS
(([email protected];))
Kopran Says Unit Kopran Research Laboratories' Deal With Abhinandan Rasayan To Buy Assets Of Manufacturing Facility Terminated
May 23 (Reuters) - Kopran Ltd KPRN.NS:
UNIT KOPRAN RESEARCH LABORATORIES' DEAL WITH ABHINANDAN RASAYAN TO BUY ASSETS OF MANUFACTURING FACILITY TERMINATED
Source text for Eikon: ID:nBSE4DdQdp
Further company coverage: KPRN.NS
(([email protected];;))
May 23 (Reuters) - Kopran Ltd KPRN.NS:
UNIT KOPRAN RESEARCH LABORATORIES' DEAL WITH ABHINANDAN RASAYAN TO BUY ASSETS OF MANUFACTURING FACILITY TERMINATED
Source text for Eikon: ID:nBSE4DdQdp
Further company coverage: KPRN.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Kopran do?
Kopran Limited is a pharmaceutical company that manufactures Active Pharmaceutical Ingredients and Finished Dosage Forms, with a wide range of products for international markets. It also offers specialty products and operates subsidiaries in research and life sciences.
Who are the competitors of Kopran?
Kopran major competitors are Shree Ganesh Remed., NGL Fine-Chem, Themis Medicare, Nectar Lifesciences, Everest Organics, SMS Lifesciences, Hester Biosciences. Market Cap of Kopran is ₹932 Crs. While the median market cap of its peers are ₹649 Crs.
Is Kopran financially stable compared to its competitors?
Kopran seems to be less financially stable compared to its competitors. Altman Z score of Kopran is 4.47 and is ranked 4 out of its 8 competitors.
Does Kopran pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Kopran latest dividend payout ratio is 28.38% and 3yr average dividend payout ratio is 35.06%
How has Kopran allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Kopran balance sheet?
Balance sheet of Kopran is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Kopran improving?
The profit is oscillating. The profit of Kopran is ₹38.55 Crs for TTM, ₹50.96 Crs for Mar 2024 and ₹27.23 Crs for Mar 2023.
Is the debt of Kopran increasing or decreasing?
Yes, The net debt of Kopran is increasing. Latest net debt of Kopran is ₹122 Crs as of Mar-25. This is greater than Mar-24 when it was ₹70.91 Crs.
Is Kopran stock expensive?
Kopran is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Kopran is 24.18, while 3 year average PE is 22.18. Also latest EV/EBITDA of Kopran is 15.09 while 3yr average is 15.53.
Has the share price of Kopran grown faster than its competition?
Kopran has given better returns compared to its competitors. Kopran has grown at ~19.63% over the last 7yrs while peers have grown at a median rate of 17.95%
Is the promoter bullish about Kopran?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Kopran is 44.42% and last quarter promoter holding is 44.46%
Are mutual funds buying/selling Kopran?
There is Insufficient data to gauge this.